

SUPPLEMENTARY MATERIALS

Poly lactide Acid-Based Nanoparticles for Controlled Delivery of Isoniazid and Rifampicin: Synthesis, Characterization, and *In Vitro* Release Study

Aldana R. Galiyeva*¹, Nazgul A. Yessentayeva¹, Dias T. Marsel¹, Arailym T. Daribay¹,
 Daniyar T. Sadyrbekov¹, Rouslan I. Moustafine², Tatyana V. Kutulutsкая³

¹Karaganda Buketov University, Karaganda, Kazakhstan

²Institute of Pharmacy, Kazan State Medical University, Kazan, Russia

³“Regional Center of Phthisiopulmonology” of the Health Department of Karaganda region, Karaganda, Kazakhstan

(*Corresponding author's e-mail: aldana_karaganda@mail.ru)

List of Content

Size distribution by volume of PLA-INH-RFP nanoparticles measured by dynamic light scattering (DLS) (Figure S1)	S1
HPLC chromatogram showing the separation of isoniazid (at 1.102 min) and rifampicin (at 7.306 min) (Figure S2)	S2

The optimized nanoparticles exhibited optimal properties consisting of 197 ± 8 nm average size and 0.287 ± 0.048 polydispersity values.




Figure S1. Size distribution by volume of PLA-INH-RFP nanoparticles measured by dynamic light scattering (DLS).

We determined isoniazid and rifampicin simultaneously by HPLC. HPLC chromatograms show separation for isoniazid and rifampicin (Figure S2). Each drug leaves the HPLC column at a specific time.




Figure S2. HPLC chromatogram showing the separation of isoniazid (at 1.102 min) and rifampicin (at 7.306 min)